TAC方案联合卡培他滨对晚期乳腺癌患者的疗效分析及对血清肿瘤标志物的影响

Effect of TAC regimen combined with capecitabine on patients with advanced breast cancer and its effect on serum tumor markers

目的:探讨TAC方案联合卡培他滨对晚期乳腺癌患者的疗效分析及对血清肿瘤标志物的影响。方法:本组研究对象选取2014年10月至2016年12月本院收治的120例乳腺癌患者,根据患者的选择分为观察组和对照组,各60例。观察组采用TAC方案联合卡培他滨治疗,对照组采用TAC方案治疗。比较两组患者近期疗效、肿瘤标志物、血清细胞因子、生存情况、毒副作用发生情况。结果:观察组的ORR和DCR(56. 7%、86. 7%)显著高于对照组(33. 3%、68. 3%)(P <0. 05)。观察组CEA、CA125、CA15-3水平均显著低于对照组(P <0. 05)。观察组血清P53、VEGF、MMP-9水平均显著低于对照组(P <0. 05)。观察组TTP、OS及1年生存率均显著高于对照组(P <0. 05)。两组毒副作用发生率的差异无统计学意义(P> 0. 05)。结论:TAC方案联合卡培他滨治疗晚期乳腺癌疗效显著,可有效改善血清肿瘤标志物,减少复发率,提高生存率。

Objective： To investigate the effect of TAC regimen combined with capecitabine in the treatment of advanced breast cancer and its effect on serum tumor markers. Methods： 120 patients with breast cancer from October 2014 to December 2016 were divided into observation group and control group,each group had 60 cases.The observation group was treated with TAC regimen combined with capecitabine,while the control group was treated with TAC regimen.The short-term efficacy,tumor markers,serim cytokines,survival status and side effects were compared between the two groups. Results： The ORR and DCR （56.7%,86.7%） of the observation group were significantly higher than that of the control group （33.3%,68.3%）（ P 〈0.05）.The levels of CEA,CA125,CA15-3 in the observation group were significantly lower than those in the control group （ P 〈0.05）.The level of P53,VEGF,MMP-9 in the observation group were significantly lower than those in the control group （ P 〈0.05）.The TTP,OS and 1 year survival rate in the observation group were significantly higher than those in the control group （ P 〈0.05）.There was no significant difference in the incidence of side effects between the two groups （P 〉0.05）. Conclusion： TAC and capecitabine is effective in the treatment of advanced breast cancer,which can effectively improve serum tumor markers,reduce recurrence rate and improve survival rate.